Escitalopram + Placebo oral tablet
ApprovedActive 1 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Obsessive-Compulsive Disorder/High Compulsive Individuals
Conditions
Obsessive-Compulsive Disorder/High Compulsive Individuals, Healthy Individuals
Trial Timeline
Apr 1, 2020 → Dec 31, 2027
NCT ID
NCT04336228About Escitalopram + Placebo oral tablet
Escitalopram + Placebo oral tablet is a approved stage product being developed by Lundbeck for Obsessive-Compulsive Disorder/High Compulsive Individuals. The current trial status is active. This product is registered under clinical trial identifier NCT04336228. Target conditions include Obsessive-Compulsive Disorder/High Compulsive Individuals, Healthy Individuals.
What happened to similar drugs?
1 of 3 similar drugs in Obsessive-Compulsive Disorder/High Compulsive Individuals were approved
Approved (1) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
20
Activity
12
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04336228 | Approved | Active |
Competing Products
8 competing products in Obsessive-Compulsive Disorder/High Compulsive Individuals
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Bitopertin + Placebo + SSRI | Roche | Phase 2 | 35 |
| pregabalin + Placebo | Pfizer | Approved | 43 |
| Sertraline + Levetiracetam + Placebo | UCB | Phase 2/3 | 30 |
| Valbenazine + Placebo | Neurocrine Biosciences | Phase 2 | 39 |
| Troriluzole + Placebo | Biohaven | Phase 3 | 34 |
| Troriluzole + Placebo | Biohaven | Phase 3 | 34 |
| Troriluzole + Placebo | Biohaven | Phase 2/3 | 32 |
| Nitrous Oxide + Nitrogen | Brain Biotech | Phase 2 | 32 |